JPRN-UMIN000000762
Completed
未知
Phase II study of Rituximab in Patients with Systemic Lupus Erythematosus - Compassionate open study of Rituximab in Systemic lupus Erythematosus
ConditionsSystemic lupus erythematosus
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Systemic lupus erythematosus
- Sponsor
- Zenyaku Kogyo Co., Ltd.
- Enrollment
- 70
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Proteinuria\>1\.0g/24hr 2\)APS complication 3\)Pregnant women or lactating mothers 4\)Positive HIV, HCV, HBs, HBc etc.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)Diffuse large B-cell lymphomaJPRN-UMIN000001050Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)40
Active, not recruiting
Not Applicable
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
Completed
Not Applicable
Phase II study of rituximab in patients with severe systemic lupus erythematosusSystemic lupus erythematosusJPRN-UMIN000000763Zenyaku Kogyo Co., Ltd.30
Active, not recruiting
Not Applicable
Phase II Trial of Rituximab Plus 2CdA in Patients with Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)ymphoma of the Mucosa-Associated Lymphoid Tissue (MALT)MedDRA version: 9.1Level: LLTClassification code 10060707Term: MALT lymphomaEUCTR2008-000767-41-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Recruiting
Phase 2
Safety and Efficacy of Rituximab in patients with juvenile dermatomyositisJuvenile dermatomyositis.Juvenile dermatomyositisM33.0IRCT20231119060108N1Shahid Beheshti University of Medical Sciences7